{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:46:21Z","timestamp":1792291581296,"version":"4.4.0"},"reference-count":178,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Depression is a prevalent and disabling disorder that poses serious problems in mental health care, and rapid antidepressants are novel treatments for this disorder. Cannabidiol (CBD), a nonintoxicating phytocannabinoid, is thought to have therapeutic potential due to its important neurological and anti-inflammatory properties. Despite major advances in pharmacotherapy in experimental animals, the exact mechanism of antidepressant-like effects remains to be elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this paper, we review the current state of knowledge on the antidepressant properties of CBD in numerous experimental and clinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Accumulating evidence suggests that CBD has antidepressant properties in humans and animals with few side effects, suggesting that CBD may be a potential antidepressant. Furthermore, we discuss that CBD may therefore provide a potential treatment to exert antidepressant-like effects through various molecular targets, reducing inflammation, and enhancing neurogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Taken together with the growing popularity of CBD as a medicine, these findings extend the limited knowledge on the antidepressant effects of CBD. This potentially opens up new therapeutic means for the patients with depression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyae064","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T23:27:43Z","timestamp":1733354863000},"source":"Crossref","is-referenced-by-count":28,"title":["A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPAR\u03b3 receptors"],"prefix":"10.1093","volume":"28","author":[{"given":"Yang","family":"Miao","sequence":"first","affiliation":[{"name":"Department of Pharmacology, The First People\u2019s Hospital of Yancheng , Yancheng, Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Jiangyin Hospital of Traditional Chinese Medicine , Jiangyin, Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-3456","authenticated-orcid":false,"given":"Wei","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmacy College, Nantong University , Nantong, Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2025030500333217000_CIT0001","doi-asserted-by":"crossref","first-page":"105542","DOI":"10.1016\/j.phrs.2021.105542","article-title":"The receptor hypothesis and the pathogenesis of depression: genetic bases and biological correlates","volume":"167","author":"Wang","year":"2021","journal-title":"Pharmacol Res."},{"key":"2025030500333217000_CIT0002","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.amjmed.2006.05.059","article-title":"Assessing and treating depression in primary care medicine","volume":"120","author":"Gelenberg","year":"2007","journal-title":"Am J Med."},{"key":"2025030500333217000_CIT0003","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1037\/a0035720","article-title":"Pathways from teacher depression and child-care quality to child behavioral problems","volume":"82","author":"Jeon","year":"2014","journal-title":"J Consult Clin Psychol."},{"key":"2025030500333217000_CIT0004","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2174\/1570159x1304150831150507","article-title":"The effects of psychological stress on depression","volume":"13","author":"Yang","year":"2015","journal-title":"Curr Neuropharmacol."},{"key":"2025030500333217000_CIT0005","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1038\/s41380-023-02056-5","article-title":"Effects of acute stress and depression on functional connectivity between prefrontal cortex and the amygdala","volume":"28","author":"Hossein","year":"2023","journal-title":"Mol Psychiatry."},{"key":"2025030500333217000_CIT0006","doi-asserted-by":"crossref","first-page":"239","DOI":"10.31887\/DCNS.2009.11.3\/rsduman","article-title":"Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression","volume":"11","author":"Duman","year":"2009","journal-title":"Dialogues Clin Neurosci."},{"key":"2025030500333217000_CIT0007","doi-asserted-by":"crossref","first-page":"110053","DOI":"10.1016\/j.pnpbp.2020.110053","article-title":"Repressor element 1 silencing transcription factor \/neuron-restrictive silencing factor (REST\/NRSF) in social stress and depression","volume":"104","author":"Soga","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"2025030500333217000_CIT0008","doi-asserted-by":"publisher","first-page":"397","DOI":"10.31887\/DCNS.2019.21.4\/ebinder","article-title":"Epigenetics and depression","volume":"21","author":"Penner-Goeke","year":"2019","journal-title":"Dialogues Clin Neurosci."},{"key":"2025030500333217000_CIT0009","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/jama.298.14.1685","article-title":"Psychological stress and disease","volume":"298","author":"Cohen","year":"2007","journal-title":"JAMA."},{"key":"2025030500333217000_CIT0010","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11886-018-1064-x","article-title":"The utility of rodent models of stress for disentangling individual vulnerability to depression and cardiovascular comorbidity","volume":"20","author":"Carnevali","year":"2018","journal-title":"Curr Cardiol Rep."},{"key":"2025030500333217000_CIT0011","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbr.2017.12.025","article-title":"Understanding the pathophysiology of depression: from monoamines to the neurogenesis hypothesis model \u2013 are we there yet","volume":"341","author":"Jesulola","year":"2018","journal-title":"Behav Brain Res."},{"key":"2025030500333217000_CIT0012","doi-asserted-by":"crossref","first-page":"101943","DOI":"10.1016\/j.cpr.2020.101943","article-title":"The gut microbiota in anxiety and depression - a systematic review","volume":"83","author":"Simpson","year":"2021","journal-title":"Clin Psychol Rev."},{"key":"2025030500333217000_CIT0013","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2105\/ajph.90.4.602","article-title":"Psychiatric morbidity, service use, and need for care in the general population: results of The Netherlands Mental Health Survey and Incidence Study","volume":"90","author":"Bijl","year":"2000","journal-title":"Am J Public Health."},{"key":"2025030500333217000_CIT0014","doi-asserted-by":"crossref","first-page":"e1147","DOI":"10.4088\/JCP.14052wc1c","article-title":"Using mechanism of action to choose medications for treatment-resistant depression","volume":"76","author":"Thase","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"2025030500333217000_CIT0015","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J Psychiatr Res."},{"key":"2025030500333217000_CIT0016","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1176\/appi.ajp.2020.20010018","article-title":"Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial","volume":"178","author":"Dwyer","year":"2021","journal-title":"Am J Psychiatry."},{"key":"2025030500333217000_CIT0017","doi-asserted-by":"publisher","first-page":"e2417786","DOI":"10.1001\/jamanetworkopen.2024.17786","article-title":"Ketamine vs electroconvulsive therapy for treatment-resistant depression: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jha","year":"2024","journal-title":"JAMA Netw Open."},{"key":"2025030500333217000_CIT0018","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/s41591-024-03063-x","article-title":"Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial","volume":"30","author":"Glue","year":"2024","journal-title":"Nat Med."},{"key":"2025030500333217000_CIT0019","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","article-title":"Long-term safety of ketamine and esketamine in treatment of depression","volume":"21","author":"Nikayin","year":"2022","journal-title":"Expert Opin Drug Saf."},{"key":"2025030500333217000_CIT0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/bs.pbr.2023.01.004","article-title":"Electroconvulsive therapy for treatment-resistant depression","volume":"281","author":"Hsieh","year":"2023","journal-title":"Prog Brain Res."},{"key":"2025030500333217000_CIT0021","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.psc.2018.04.001","article-title":"Electroconvulsive therapy in depression: current practice and future direction","volume":"41","author":"Hermida","year":"2018","journal-title":"Psychiatr Clin North Am."},{"key":"2025030500333217000_CIT0022","doi-asserted-by":"publisher","first-page":"22f14733","DOI":"10.4088\/JCP.22f14733","article-title":"Insights for the use of ketamine from randomized controlled trials that compared ketamine with electroconvulsive therapy in severe depression","volume":"83","author":"Andrade","year":"2022","journal-title":"J Clin Psychiatry."},{"key":"2025030500333217000_CIT0023","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/1028415X.2015.1103461","article-title":"Natural products, micronutrients, and nutraceuticals for the treatment of depression: a short review","volume":"20","author":"Nabavi","year":"2017","journal-title":"Nutr Neurosci."},{"key":"2025030500333217000_CIT0024","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1188\/17.CJON.409","article-title":"Cannabis guidelines","volume":"21","author":"Kennedy Sheldon","year":"2017","journal-title":"Clin J Oncol Nurs."},{"key":"2025030500333217000_CIT0025","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fpls.2016.00019","article-title":"Cannabis sativa: the plant of the thousand and one molecules","volume":"7","author":"Andre","year":"2016","journal-title":"Front Plant Sci."},{"key":"2025030500333217000_CIT0026","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.1002\/ptr.7213","article-title":"Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L: an overview","volume":"35","author":"Kumar","year":"2021","journal-title":"Phytother Res."},{"key":"2025030500333217000_CIT0027","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000521683","article-title":"Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals,","volume":"107","author":"Legare","year":"2022","journal-title":"Pharmacology."},{"key":"2025030500333217000_CIT0028","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/toxins13020117","article-title":"Cannabis: a toxin-producing plant with potential therapeutic uses","volume":"13","author":"Breijyeh","year":"2021","journal-title":"Toxins (Basel)."},{"key":"2025030500333217000_CIT0029","doi-asserted-by":"crossref","first-page":"624275","DOI":"10.3389\/fpsyt.2020.624275","article-title":"Prenatal cannabinoid exposure: emerging evidence of physiological and neuropsychiatric abnormalities","volume":"11","author":"Nashed","year":"2020","journal-title":"Front Psychiatry."},{"key":"2025030500333217000_CIT0030","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.120.000340","article-title":"The pharmacological case for cannabigerol","volume":"376","author":"Nachnani","year":"2021","journal-title":"J Pharmacol Exp Ther."},{"key":"2025030500333217000_CIT0031","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol."},{"key":"2025030500333217000_CIT0032","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","article-title":"A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis","volume":"7","author":"Granja","year":"2012","journal-title":"J Neuroimmune Pharmacol."},{"key":"2025030500333217000_CIT0033","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","article-title":"Cannabidiol: state of the art and new challenges for therapeutic applications","volume":"175","author":"Pisanti","year":"2017","journal-title":"Pharmacol Ther."},{"key":"2025030500333217000_CIT0034","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1007\/s11606-020-06504-8","article-title":"Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review","volume":"36","author":"Balachandran","year":"2021","journal-title":"J Gen Intern Med."},{"key":"2025030500333217000_CIT0035","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.3390\/ijms24032052","article-title":"Cannabidiol modulates alterations in PFC microRNAs in a rat model of depression","volume":"24","author":"Bright","year":"2023","journal-title":"Int J Mol Sci ."},{"key":"2025030500333217000_CIT0036","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/095952874302600116","article-title":"Observations on the medicinal properties of the Cannabis sativa of India","volume":"26","author":"Clendinning","year":"1843","journal-title":"Med Chir Trans."},{"key":"2025030500333217000_CIT0037","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bmj.s1-5.123.363","article-title":"On the preparations of the Indian hemp, or Gunjah: Cannabis indica their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases","volume":"s1-5","author":"O\u2019Shaughnessy","year":"1843","journal-title":"Provincial Med J Retrospect Med Sci."},{"key":"2025030500333217000_CIT0038","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaac.2019.10.003","article-title":"Editorial: brain mediators of the cannabis-prodromal psychosis connection","volume":"59","author":"Lange","year":"2020","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"2025030500333217000_CIT0039","author":"W.H. Organization","year":"2016","journal-title":"The Health and Social Effects of Nonmedical Cannabis Use"},{"key":"2025030500333217000_CIT0040","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1107\/S0567740877010577","article-title":"Cannabidiol","volume":"33","author":"Jones","year":"1977","journal-title":"Acta Crystallogr B."},{"key":"2025030500333217000_CIT0041","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.3390\/molecules28073271","article-title":"The polypharmacological effects of cannabidiol","volume":"28","author":"Castillo-Arellano","year":"2023","journal-title":"Molecules."},{"key":"2025030500333217000_CIT0042","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/ja01858a058","article-title":"Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I","volume":"62","author":"Adams","year":"1940","journal-title":"J Am Chem Soc."},{"key":"2025030500333217000_CIT0043","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-x","article-title":"Hashish. I. The structure of cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron."},{"key":"2025030500333217000_CIT0044","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: an overview of some pharmacological aspects,","volume":"42","author":"Mechoulam","year":"2002","journal-title":"J Clin Pharmacol."},{"key":"2025030500333217000_CIT0045","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antiox9010021","article-title":"Antioxidative and anti-inflammatory properties of cannabidiol","volume":"9","author":"Atalay","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"2025030500333217000_CIT0046","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41386-019-0473-x","article-title":"MDMA enhances pleasantness of affective touch","volume":"45","author":"de Wit","year":"2020","journal-title":"Neuropsychopharmacology."},{"key":"2025030500333217000_CIT0047","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-3-030-69186-8_16","volume-title":"Cannabidiol (Epidiolex), Cannabinoids and Pain","author":"Harrison","year":"2021"},{"key":"2025030500333217000_CIT0048","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5863\/1551-6776-25.6.485","article-title":"Emerging use of epidiolex (cannabidiol) in epilepsy","volume":"25","author":"Abu-Sawwa","year":"2020","journal-title":"J Pediatr Pharmacol Ther."},{"key":"2025030500333217000_CIT0049","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000489287","article-title":"The trouble with CBD oil","volume":"1","author":"Hazekamp","year":"2018","journal-title":"Med Cannabis Cannabinoids."},{"key":"2025030500333217000_CIT0050","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia."},{"key":"2025030500333217000_CIT0051","first-page":"279","article-title":"Metabolism and pharmacokinetics of the cannabinoids","volume-title":"Biochemistry and Physiology of Substande Abuse.","author":"Harvey","year":"1991"},{"key":"2025030500333217000_CIT0052","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","article-title":"Cannabidiol: pharmacology and therapeutic targets","volume":"238","author":"Britch","year":"2021","journal-title":"Psychopharmacology (Berl)."},{"key":"2025030500333217000_CIT0053","first-page":"35","volume-title":"A Single Centre, Placebo-Controlled, Four Period, Crossover, Tolerability Study Assessing, Pharmacodynamic Effects, Pharmacokinetic Characteristics and Cognitive Profiles of a Single Dose of Three Formulations of Cannabis Based Medicine Extracts (CBMEs)(GWPD9901), Plus A Two Period Tolerability Study Comparing Pharmacodynamic Effects and Pharmacokinetic Characteristics of a Single Dose of a Cannabis Based Medicine Extract Given Via Two Administration Routes (GWPD9901 EXT)","author":"Guy","year":"2014"},{"key":"2025030500333217000_CIT0054","first-page":"79","volume-title":"A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20\u00a0mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of CBME per Oral in Healthy Male and Female Volunteers (GWPK0112).","author":"Guy","year":"2014"},{"key":"2025030500333217000_CIT0055","first-page":"121","volume-title":"A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215),","author":"Guy","year":"2014"},{"key":"2025030500333217000_CIT0056","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","article-title":"Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial","volume":"88","author":"Schoedel","year":"2018","journal-title":"Epilepsy Behav."},{"key":"2025030500333217000_CIT0057","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"2025030500333217000_CIT0058","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.16093","article-title":"Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy","volume":"60","author":"Birnbaum","year":"2019","journal-title":"Epilepsia."},{"key":"2025030500333217000_CIT0059","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0091-3057(91)90357-8","article-title":"Assay of plasma cannabidiol by capillary gas chromatography\/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav."},{"key":"2025030500333217000_CIT0060","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology."},{"key":"2025030500333217000_CIT0061","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/bms.1200130206","article-title":"Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration","volume":"13","author":"Ohlsson","year":"1986","journal-title":"Biomed Environ Mass Spectrom."},{"key":"2025030500333217000_CIT0062","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified Cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs."},{"key":"2025030500333217000_CIT0063","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/jcph.1412","article-title":"A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment","volume":"59","author":"Taylor","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"2025030500333217000_CIT0064","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40263-019-00624-4","article-title":"Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy","volume":"33","author":"Wheless","year":"2019","journal-title":"CNS Drugs."},{"key":"2025030500333217000_CIT0065","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/01.ftd.0000177223.19294.5c","article-title":"Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract","volume":"27","author":"Nadulski","year":"2005","journal-title":"Ther Drug Monit."},{"key":"2025030500333217000_CIT0066","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1373\/clinchem.2010.152439","article-title":"Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration","volume":"57","author":"Karschner","year":"2011","journal-title":"Clin Chem."},{"key":"2025030500333217000_CIT0067","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1373\/clinchem.2011.177881","article-title":"Cannabinoid disposition in oral fluid after controlled smoked cannabis","volume":"58","author":"Lee","year":"2012","journal-title":"Clin Chem."},{"key":"2025030500333217000_CIT0068","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.xphs.2017.12.020","article-title":"PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers","volume":"107","author":"Atsmon","year":"2018","journal-title":"J Pharm Sci."},{"key":"2025030500333217000_CIT0069","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2017.09.011","article-title":"Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration","volume":"266","author":"Cherniakov","year":"2017","journal-title":"J Control Release."},{"key":"2025030500333217000_CIT0070","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00228-012-1441-0","article-title":"A phase I study to assess the single and multiple dose pharmacokinetics of THC\/CBD oromucosal spray","volume":"69","author":"Stott","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"2025030500333217000_CIT0071","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front Pharmacol."},{"key":"2025030500333217000_CIT0072","first-page":"205","article-title":"Metabolism and pharmacokinetics of cannabinoids","volume-title":"The Medicinal Uses of Cannabis and Cannabinoids","author":"Hawksworth","year":"2004"},{"key":"2025030500333217000_CIT0073","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0090-9556(25)06962-4","article-title":"Pharmacokinetics of cannabidiol in dogs","volume":"16","author":"Samara","year":"1988","journal-title":"Drug Metab Dispos."},{"key":"2025030500333217000_CIT0074","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem Biodivers."},{"key":"2025030500333217000_CIT0075","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","article-title":"Critical aspects affecting Cannabidiol oral bioavailability and metabolic elimination, and related clinical implications","volume":"34","author":"Perucca","year":"2020","journal-title":"CNS Drugs."},{"key":"2025030500333217000_CIT0076","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes,","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci."},{"key":"2025030500333217000_CIT0077","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00228-012-1393-4","article-title":"A phase I study to assess the effect of food on the single dose bioavailability of the THC\/CBD oromucosal spray","volume":"69","author":"Stott","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"2025030500333217000_CIT0078","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cpdd.36","article-title":"A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT\/QTc study to evaluate the electrophysiologic effects of THC\/CBD spray","volume":"2","author":"Sellers","year":"2013","journal-title":"Clin Pharmacol Drug Dev."},{"key":"2025030500333217000_CIT0079","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejps.2017.07.003","article-title":"The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model","volume":"109","author":"Cherniakov","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"2025030500333217000_CIT0080","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1155\/2001\/469629","article-title":"Medicinal use of cannabis: history and current status","volume":"6","author":"Kalant","year":"2001","journal-title":"Pain Res Manag."},{"key":"2025030500333217000_CIT0081","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol Pharmacol."},{"key":"2025030500333217000_CIT0082","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu Rev Psychol."},{"key":"2025030500333217000_CIT0083","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1073\/pnas.95.14.8375","article-title":"The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation","volume":"95","author":"De Petrocellis","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2025030500333217000_CIT0084","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA,","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature."},{"key":"2025030500333217000_CIT0085","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature."},{"key":"2025030500333217000_CIT0086","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s0378-1119(02)01094-6","article-title":"The invertebrate ancestry of endocannabinoid signalling: an orthologue of vertebrate cannabinoid receptors in the urochordate Ciona intestinalis","volume":"302","author":"Elphick","year":"2003","journal-title":"Gene."},{"key":"2025030500333217000_CIT0087","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/bbrc.1995.2437","article-title":"2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain","volume":"215","author":"Sugiura","year":"1995","journal-title":"Biochem Biophys Res Commun."},{"key":"2025030500333217000_CIT0088","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev."},{"key":"2025030500333217000_CIT0089","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev."},{"key":"2025030500333217000_CIT0090","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/biof.131","article-title":"Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol","volume":"37","author":"Ueda","year":"2011","journal-title":"Biofactors."},{"key":"2025030500333217000_CIT0091","article-title":"Optimization and characterization of a triazole urea inhibitor for diacylglycerol lipase beta (DAGL-\u03b2). In:","volume-title":"Probe Reports from the NIH Molecular Libraries Program","author":"Hsu","year":"2013"},{"key":"2025030500333217000_CIT0092","doi-asserted-by":"publisher","first-page":"136064","DOI":"10.1016\/j.neulet.2021.136064","article-title":"The endocannabinoid system as a therapeutic target for schizophrenia: failures and potentials","volume":"759","author":"Seillier","year":"2021","journal-title":"Neurosci Lett."},{"key":"2025030500333217000_CIT0093","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1194\/jlr.M030411","article-title":"Biochemical and pharmacological characterization of human \u03b1\/\u03b2-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12)","volume":"53","author":"Navia-Paldanius","year":"2012","journal-title":"J Lipid Res."},{"key":"2025030500333217000_CIT0094","first-page":"14","article-title":"Pharmacology of cannabinoids","volume":"25","author":"Grotenhermen","year":"2004","journal-title":"Neuro Endocrinol Lett."},{"key":"2025030500333217000_CIT0095","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br J Pharmacol."},{"key":"2025030500333217000_CIT0096","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1523\/JNEUROSCI.4212-08.2009","article-title":"Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels","volume":"29","author":"Ryan","year":"2009","journal-title":"J Neurosci."},{"key":"2025030500333217000_CIT0097","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.3390\/ijms22041863","article-title":"Cannabidiol as a potential treatment for anxiety and mood disorders: molecular targets and epigenetic insights from preclinical research","volume":"22","author":"Melas","year":"2021","journal-title":"Int J Mol Sci."},{"key":"2025030500333217000_CIT0098","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of Cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics."},{"key":"2025030500333217000_CIT0099","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40263-018-0539-z","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention","volume":"32","author":"Leweke","year":"2018","journal-title":"CNS Drugs."},{"key":"2025030500333217000_CIT0100","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol."},{"key":"2025030500333217000_CIT0101","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br J Pharmacol."},{"key":"2025030500333217000_CIT0102","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/s0896-6273(00)80564-4","article-title":"The cloned capsaicin receptor integrates multiple pain-producing stimuli","volume":"21","author":"Tominaga","year":"1998","journal-title":"Neuron."},{"key":"2025030500333217000_CIT0103","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.fitote.2016.05.008","article-title":"Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages","volume":"112","author":"Rajan","year":"2016","journal-title":"Fitoterapia."},{"key":"2025030500333217000_CIT0104","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem Neurosci."},{"key":"2025030500333217000_CIT0105","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res."},{"key":"2025030500333217000_CIT0106","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.phrs.2010.05.003","article-title":"Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors","volume":"62","author":"Alves","year":"2010","journal-title":"Pharmacol Res."},{"key":"2025030500333217000_CIT0107","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","article-title":"Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-possible involvement of 5-HT1A and CB1 receptors","volume":"303","author":"Sartim","year":"2016","journal-title":"Behav Brain Res."},{"key":"2025030500333217000_CIT0108","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.neuron.2023.01.018","article-title":"Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity,","volume":"111","author":"Rosenberg","year":"2023","journal-title":"Neuron."},{"key":"2025030500333217000_CIT0109","doi-asserted-by":"publisher","first-page":"109715","DOI":"10.1016\/j.neuropharm.2023.109715","article-title":"Restoring prefrontal cortical excitation-inhibition balance with cannabidiol ameliorates neurobehavioral abnormalities in a mouse model of neurodevelopmental disorders","volume":"240","author":"Zhang","year":"2023","journal-title":"Neuropharmacology."},{"key":"2025030500333217000_CIT0110","doi-asserted-by":"publisher","first-page":"837946","DOI":"10.3389\/fpsyt.2022.837946","article-title":"Cannabidiol (CBD) in the self-treatment of depression-exploratory study and a new phenomenon of concern for psychiatrists","volume":"13","author":"Wieckiewicz","year":"2022","journal-title":"Front Psychiatry."},{"key":"2025030500333217000_CIT0111","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42238-021-00078-w","article-title":"Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic","volume":"3","author":"Rapin","year":"2021","journal-title":"J Cannabis Res."},{"key":"2025030500333217000_CIT0112","doi-asserted-by":"crossref","first-page":"729800","DOI":"10.3389\/fpsyt.2021.729800","article-title":"Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial","volume":"12","author":"Martin","year":"2021","journal-title":"Front Psychiatry"},{"key":"2025030500333217000_CIT0113","doi-asserted-by":"publisher","first-page":"21m14130","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial","volume":"83","author":"Berger","year":"2022","journal-title":"J Clin Psychiatry."},{"key":"2025030500333217000_CIT0114","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40211-020-00334-0","article-title":"Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression","volume":"35","author":"Laczkovics","year":"2021","journal-title":"Neuropsychiatr."},{"key":"2025030500333217000_CIT0115","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/S0033291719003519","article-title":"Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis","volume":"51","author":"O\u2019Neill","year":"2021","journal-title":"Psychol Med."},{"key":"2025030500333217000_CIT0116","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1176\/appi.ps.202000189","article-title":"Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review","volume":"72","author":"Stanciu","year":"2021","journal-title":"Psychiatr Serv."},{"key":"2025030500333217000_CIT0117","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.2174\/138161212802884780","article-title":"Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers","volume":"18","author":"Martin-Santos","year":"2012","journal-title":"Curr Pharm Des."},{"key":"2025030500333217000_CIT0118","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/07067437231209650","article-title":"Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study: Le cannabidiol comme traitement d\u2019appoint de la d\u00e9pression bipolaire aigu\u00eb: une \u00e9tude pilote","volume":"69","author":"Pinto","year":"2024","journal-title":"Can J Psychiatry."},{"key":"2025030500333217000_CIT0119","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr Drug Saf."},{"key":"2025030500333217000_CIT0120","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s42238-023-00186-9","article-title":"The therapeutic potential of purified cannabidiol","volume":"5","author":"O\u2019Sullivan","year":"2023","journal-title":"J Cannabis Res."},{"key":"2025030500333217000_CIT0121","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br J Pharmacol."},{"key":"2025030500333217000_CIT0122","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0278-5846(93)90034-p","article-title":"5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action","volume":"17","author":"Schreiber","year":"1993","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"2025030500333217000_CIT0123","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bbr.2012.03.020","article-title":"Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation","volume":"231","author":"Farooq","year":"2012","journal-title":"Behav Brain Res."},{"key":"2025030500333217000_CIT0124","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology."},{"key":"2025030500333217000_CIT0125","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/jrms.JRMS_879_17","article-title":"Serum-based microRNA biomarkers for major depression: MiR-16, miR-135a, and miR-1202","volume":"23","author":"Gheysarzadeh","year":"2018","journal-title":"J Res Med Sci."},{"key":"2025030500333217000_CIT0126","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jad.2015.02.022","article-title":"CSF miR-16 is decreased in major depression patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter system","volume":"178","author":"Song","year":"2015","journal-title":"J Affect Disord."},{"key":"2025030500333217000_CIT0127","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s12035-018-1143-4","article-title":"Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex","volume":"56","author":"Sales","year":"2019","journal-title":"Mol Neurobiol."},{"key":"2025030500333217000_CIT0128","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bbr.2007.01.003","article-title":"Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety","volume":"178","author":"Wang","year":"2007","journal-title":"Behav Brain Res."},{"key":"2025030500333217000_CIT0129","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/s0163-7258(97)00004-1","article-title":"The olfactory bulbectomized rat as a model of depression: an update","volume":"74","author":"Kelly","year":"1997","journal-title":"Pharmacol Ther."},{"key":"2025030500333217000_CIT0130","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neubiorev.2005.03.010","article-title":"The olfactory bulbectomised rat as a model of depression,","volume":"29","author":"Song","year":"2005","journal-title":"Neurosci Biobehav Rev."},{"key":"2025030500333217000_CIT0131","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.pnpbp.2006.06.004","article-title":"Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test","volume":"30","author":"Moreira","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"2025030500333217000_CIT0132","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1691\/ph.2017.7474","article-title":"Role of the endocannabinoid system in the formation and development of depression","volume":"72","author":"Zhou","year":"2017","journal-title":"Pharmazie."},{"key":"2025030500333217000_CIT0133","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1517\/14728222.12.11.1347","article-title":"The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets","volume":"12","author":"Bambico","year":"2008","journal-title":"Expert Opin Ther Targets."},{"key":"2025030500333217000_CIT0134","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","article-title":"Involvement of CB1 cannabinoid receptors in emotional behaviour","volume":"159","author":"Martin","year":"2002","journal-title":"Psychopharmacology (Berl)."},{"key":"2025030500333217000_CIT0135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2018.06.006","article-title":"Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats","volume":"682","author":"de Morais","year":"2018","journal-title":"Neurosci Lett."},{"key":"2025030500333217000_CIT0136","doi-asserted-by":"publisher","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","article-title":"Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex","volume":"27","author":"Bambico","year":"2007","journal-title":"J Neurosci."},{"key":"2025030500333217000_CIT0137","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1161\/01.STR.0000163083.59201.34","article-title":"Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism","volume":"36","author":"Mishima","year":"2005","journal-title":"Stroke."},{"key":"2025030500333217000_CIT0138","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11011-020-00667-3","article-title":"Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action","volume":"36","author":"Chaves","year":"2021","journal-title":"Metab Brain Dis."},{"key":"2025030500333217000_CIT0139","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1002\/cpz1.78","article-title":"Streptozotocin-induced diabetic models in mice and rats","volume":"1","author":"Furman","year":"2021","journal-title":"Curr Protoc."},{"key":"2025030500333217000_CIT0140","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1476-5381.2010.00729.x","article-title":"CB2: a cannabinoid receptor with an identity crisis","volume":"160","author":"Atwood","year":"2010","journal-title":"Br J Pharmacol."},{"key":"2025030500333217000_CIT0141","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajpath.2011.11.003","article-title":"The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications","volume":"180","author":"Horv\u00e1th","year":"2012","journal-title":"Am J Pathol."},{"key":"2025030500333217000_CIT0142","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cbi.2015.12.019","article-title":"\u03b2-Caryophyllene, a natural sesquiterpene lactone attenuates hyperglycemia mediated oxidative and inflammatory stress in experimental diabetic rats","volume":"245","author":"Basha","year":"2016","journal-title":"Chem Biol Interact."},{"key":"2025030500333217000_CIT0143","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000320527","article-title":"Cannabinoid receptors are coupled to stimulation of insulin secretion from mouse MIN6 beta-cells,","volume":"26","author":"Li","year":"2010","journal-title":"Cell Physiol Biochem."},{"key":"2025030500333217000_CIT0144","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/ph15040473","article-title":"Cannabinoid CB1 receptor involvement in the actions of CBD on anxiety and coping behaviors in mice","volume":"15","author":"Austrich-Olivares","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025030500333217000_CIT0145","doi-asserted-by":"publisher","first-page":"109870","DOI":"10.1016\/j.neuropharm.2024.109870","article-title":"Repeated cannabidiol treatment affects neuroplasticity and endocannabinoid signaling in the prefrontal cortex of the Flinders sensitive line (FSL) rat model of depression","volume":"248","author":"Domingos","year":"2024","journal-title":"Neuropharmacology."},{"key":"2025030500333217000_CIT0146","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.neuint.2008.12.011","article-title":"A genetic rat model of depression, Flinders sensitive line, has a lower density of 5-HT(1A) receptors, but a higher density of 5-HT(1B) receptors, compared to control rats","volume":"54","author":"Nishi","year":"2009","journal-title":"Neurochem Int."},{"key":"2025030500333217000_CIT0147","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.brainresbull.2021.06.017","article-title":"Cannabidiol in the prelimbic cortex modulates the comorbid condition between the chronic neuropathic pain and depression-like behaviour in rats: the role of medial prefrontal cortex 5-HT(1A) and CB(1) receptors","volume":"174","author":"Malvestio","year":"2021","journal-title":"Brain Res Bull."},{"key":"2025030500333217000_CIT0148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tips.2005.11.003","article-title":"In silico patent searching reveals a new cannabinoid receptor","volume":"27","author":"Baker","year":"2006","journal-title":"Trends Pharmacol Sci."},{"key":"2025030500333217000_CIT0149","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1515\/jbcpp-2015-0080","article-title":"GPR55 - a putative \u201ctype 3\u201d cannabinoid receptor in inflammation","volume":"27","author":"Yang","year":"2016","journal-title":"J Basic Clin Physiol Pharmacol."},{"key":"2025030500333217000_CIT0150","doi-asserted-by":"publisher","first-page":"110153","DOI":"10.1016\/j.neuropharm.2024.110153","article-title":"Neuromolecular and behavioral effects of cannabidiol on depressive-associated behaviors and neuropathic pain conditions in mice","volume":"261","author":"Shen","year":"2024","journal-title":"Neuropharmacology."},{"key":"2025030500333217000_CIT0151","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br J Pharmacol."},{"key":"2025030500333217000_CIT0152","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.bbrc.2007.08.078","article-title":"Identification of GPR55 as a lysophosphatidylinositol receptor","volume":"362","author":"Oka","year":"2007","journal-title":"Biochem Biophys Res Commun."},{"key":"2025030500333217000_CIT0153","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1747-0285.2006.00370.x","article-title":"GPR55 as a new cannabinoid receptor: still a long way to prove it","volume":"67","author":"Petitet","year":"2006","journal-title":"Chem Biol Drug Des."},{"key":"2025030500333217000_CIT0154","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.0711278105","article-title":"GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current","volume":"105","author":"Lauckner","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2025030500333217000_CIT0155","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1124\/mol.118.111864","article-title":"Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons","volume":"94","author":"Straiker","year":"2018","journal-title":"Mol Pharmacol."},{"key":"2025030500333217000_CIT0156","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics."},{"key":"2025030500333217000_CIT0157","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/ph14100964","article-title":"Computational approach reveals pronociceptive potential of cannabidiol in osteoarthritis: role of transient receptor potential channels","volume":"14","author":"Mlost","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"2025030500333217000_CIT0158","doi-asserted-by":"publisher","first-page":"154771","DOI":"10.1016\/j.phymed.2023.154771","article-title":"Cannabidiol goes nuclear: the role of PPAR\u03b3","volume":"114","author":"Khosropoor","year":"2023","journal-title":"Phytomedicine."},{"key":"2025030500333217000_CIT0159","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O\u2019Sullivan","year":"2016","journal-title":"Br J Pharmacol."},{"key":"2025030500333217000_CIT0160","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1152\/physrev.00025.2005","article-title":"Transcriptional regulation of metabolism","volume":"86","author":"Desvergne","year":"2006","journal-title":"Physiol Rev."},{"key":"2025030500333217000_CIT0161","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1189\/jlb.2HI0317-088RR","article-title":"Frontline science: corticotropin-releasing factor receptor subtype 1 is a critical modulator of mast cell degranulation and stress-induced pathophysiology","volume":"102","author":"Ayyadurai","year":"2017","journal-title":"J Leukoc Biol."},{"key":"2025030500333217000_CIT0162","doi-asserted-by":"publisher","first-page":"658520","DOI":"10.1155\/2008\/658520","article-title":"PPAR Regulation of inflammatory signaling in CNS diseases","volume":"2008","author":"Bright","year":"2008","journal-title":"PPAR Res."},{"key":"2025030500333217000_CIT0163","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.neurobiolaging.2014.09.028","article-title":"Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression","volume":"36","author":"Kariharan","year":"2015","journal-title":"Neurobiol Aging."},{"key":"2025030500333217000_CIT0164","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/ejn.15134","article-title":"Differential contribution of CB1, CB2, 5-HT1A, and PPAR-\u03b3 receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments","volume":"53","author":"Mori","year":"2021","journal-title":"Eur J Neurosci."},{"key":"2025030500333217000_CIT0165","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40168-022-01255-6","article-title":"The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids","volume":"10","author":"Xiao","year":"2022","journal-title":"Microbiome."},{"key":"2025030500333217000_CIT0166","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.intimp.2017.05.036","article-title":"Pioglitazone attenuates lipopolysaccharide-induced depression-like behaviors, modulates NF-\u03baB\/IL-6\/STAT3, CREB\/BDNF pathways and central serotonergic neurotransmission in mice","volume":"49","author":"Liao","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"2025030500333217000_CIT0167","doi-asserted-by":"publisher","first-page":"e28668","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS One."},{"key":"2025030500333217000_CIT0168","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2741\/2802","article-title":"Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists","volume":"13","author":"Kapadia","year":"2008","journal-title":"Front Biosci."},{"key":"2025030500333217000_CIT0169","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/can.2019.0028","article-title":"Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent","volume":"5","author":"Gray","year":"2020","journal-title":"Cannabis Cannabinoid Res."},{"key":"2025030500333217000_CIT0170","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/brainsci13020314","article-title":"Dual cannabinoid and orexin regulation of anhedonic behaviour caused by prolonged restraint stress","volume":"13","author":"Kim","year":"2023","journal-title":"Brain Sci"},{"key":"2025030500333217000_CIT0171","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J Neurosci."},{"key":"2025030500333217000_CIT0172","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J Comp Neurol."},{"key":"2025030500333217000_CIT0173","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/mol.112.080523","article-title":"Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling","volume":"83","author":"J\u00e4ntti","year":"2013","journal-title":"Mol Pharmacol."},{"key":"2025030500333217000_CIT0174","first-page":"27","article-title":"CBD modulates DNA methylation in the prefrontal cortex and hippocampus of mice exposed to forced swim","volume":"388","author":"Sales","year":"1126","journal-title":"Behav Brain Res."},{"key":"2025030500333217000_CIT0175","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2174\/1871524920666200924114524","article-title":"Effects on the post-translational modification of H3K4Me3, H3K9ac, H3K9Me2, H3K27Me3, and H3K36Me2 levels in cerebral cortex, hypothalamus and pons of rats after a systemic administration of cannabidiol: a preliminary study","volume":"21","author":"Pastrana-Trejo","year":"2021","journal-title":"Cent Nerv Syst Agents Med Chem."},{"key":"2025030500333217000_CIT0176","doi-asserted-by":"publisher","first-page":"129","DOI":"10.14740\/jocmr4090","article-title":"Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials","volume":"12","author":"Larsen","year":"2020","journal-title":"J Clin Med Res."},{"key":"2025030500333217000_CIT0177","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","article-title":"Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology."},{"key":"2025030500333217000_CIT0178","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2019","journal-title":"Braz J Psychiatry."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyae064\/60972465\/pyae064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/2\/pyae064\/60972465\/pyae064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/2\/pyae064\/60972465\/pyae064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:34:00Z","timestamp":1741116840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyae064\/7918373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":178,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyae064","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,6]]},"article-number":"pyae064"}}